Nu Skin Q1 revenue falls 12% to $320.6M; exits BeautyBio, refinances debt, strips tariff risk

Filed May 8, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 9, 2025 · ~2 min read

Key Changes

• high

  Q1 2026 revenue declined 12% to $320.6M; EPS collapsed to $0.04 from $2.14 prior year (which included $176M Mavely sale gain). Company incurred $5.9M in charges to wind down BeautyBio business.

  MD&A: Financial Results verify on EDGAR →
• high

  Refinanced debt in March 2026, cutting term loan from $400M to $175M and revolver from $500M to $75M. Leverage covenant tightened from 2.75x to 2.25x. $225M outstanding as of quarter-end.

  MD&A: Credit Agreement verify on EDGAR →
• high

  Sales force metrics show continued attrition: Customers down 14%, Paid Affiliates down 8%, Sales Leaders down 13% year-over-year. Company cites 'switching costs' as Sales Leaders prioritize Prysm iO wellness platform over legacy products.

  MD&A: Sales Force verify on EDGAR →